FDA “Ministerial” Approach To Patent Listings Upheld By Appeals Court
This article was originally published in The Tan Sheet
Executive Summary
An appeals court's dismissal of Apotex' lawsuit against FDA relating to patent listings affirms a key provision in the final rule reforming Hatch/Waxman
You may also be interested in...
Califf Suggests Congress ‘Tighten Up Laws’ To Address Orange Book Abuses
US FDA Commissioner repeats longstanding FDA policy that the agency doesn’t have much power to address frivolous patent listings in the Orange Book, but seems to support Congress providing more authority.
Orange Book Policing May Increase, US FDA's Gottlieb Says
Commissioner says agency will modernize drug patent reference manual this year and consider potential changes to Orange Book administration policy. However, any transformative moves could trigger a court challenge.
Senate Generic Reform Bill Likely To Result In Earlier ANDA Filings
A bipartisan Senate bill would encourage earlier ANDA filings by generics firms to head off new innovator patent listings and secure sole rights to 180-day exclusivity